Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Richard A. Fair
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 67
- Beta
- 0.24
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 133.73
Financials
Net Income
$-32.48MEBITDA
$-32.48MFree Cash Flow
$-18.63MEPS (diluted)
$-0.49Shares Outstanding (diluted)
66.17M+1431.7%Operating Expenses
$37.21MCash & Debt
$895.15MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-103.69M | $-1.83 |
| 2024 | $0.00 | $-89.02M | $-1.89 |
| 2023 | $0.00 | $-71.58M | $-2.01 |
| 2022 | $0.00 | $-37.66M | $-6.03 |
| 2021 | $0.00 | $-24.74M | $-3.17 |
| 2020 | $0.00 | $-18.97M | $-4.31 |
| 2019 | $0.00 | $-23.46M | $-5.43 |
| 2018 | $0.00 | $-11.34M | $-2.62 |
| 2017 | $0.00 | $0.00 | $0.00 |
Valuation
ELVNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
63+38.89%Social Signal Score
Mentions (5)
- Newsbenzinga.com·4d ago·Positive
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·32d ago·Neutral
Enliven Therapeutics to Present at Upcoming Investor Conferences BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare ConferenceDate: Tuesday, Sept.
View source ↗ - Newsseekingalpha.com·33d ago·Negative
…Sequencing Enliven Therapeutics is positioned as a late-stage, well-capitalized biotech with $895M cash, funding operations into 2030 and the pivotal ENABLE-2 trial. ELVN-001 targets chronic myeloid leukemia as a selective ATP-competitive inhibitor, aiming for a differentiated, chronic-use profile in a sequential treatment paradigm. Phase 1 data show 61% MMR at 80 mg daily, with favorable safety and convenience for chronic administration, supporting potential in earlier-line CML settings.
View source ↗ - Newsbenzinga.com·48d ago·Neutral
Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as the firm initiated coverage, citing the potential for lead drug candidate ELVN-001 to reshape treatment of chronic myeloid leukemia (CML).
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.43 per share
Typical surprise +7.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.49 vs $-0.39miss
- Thu, May 7$-0.38 vs $-0.44beat
- Tue, Mar 3$-0.48 vs $-0.42miss
- Wed, Nov 12$-0.32 vs $-0.43beat
- Wed, Aug 13$-0.49 vs $-0.53beat
- Wed, May 14$-0.57 vs $-0.51miss
Estimates and results for ELVN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ELVN officers and directors.
- Bought
- —
- Sold
- $69.0m
0 trades
51 trades
- Hohl Benjaminsold
- Hohl Benjaminsold
- Hohl Benjaminsold
- Collins Helen Louisesold
- Collins Helen Louisesold
- Collins Helen Louisesold
- Hohl Benjaminsold
- Hohl Benjaminsold
49 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ELVN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.